Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of 3D Medicines Corporation.

    Client Virtual Booth

    3D MEDICINES CORPORATION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    3D Medicines Corporation
    China Flag
    Country
    Country
    China
    Address
    Address
    Block A, Building 2, No.158 Xinjunhuan Road, Pujiang Town, Minhang District, Shanghai
    Telephone
    Telephone
    (86)021-34796586
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.3dmedcare.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

    Details:

    3D189 or SLS-001 (galinpepimut-S), is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein which is present and over-expressed in an array of hematological malignancies and solid tumors.


    Lead Product(s): Galinpepimut-S,Sargramostim

    Therapeutic Area: Oncology Product Name: SLS-001

    Highest Development Status: Phase IIIProduct Type: Vaccine

    Recipient: Sellas Life Sciences Group

    Deal Size: $202.0 million Upfront Cash: $7.5 million

    Deal Type: Licensing Agreement April 06, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

    Details:

    The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).


    Lead Product(s): IgG4 monoclonal antibody

    Therapeutic Area: Oncology Product Name: IMC-002

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: ImmuneOncia Therapeutics, Inc

    Deal Size: $470.0 million Upfront Cash: $8.0 million

    Deal Type: Collaboration March 31, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search